Fulltext
Full text is available in PDF
Official Journal of Research Center for Gastroenterology and Liver Diseases
e-ISSN 1735-3408
p-ISSN 1735-143X
Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection
Authors
1Angela Maria e Antonio Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
2Hepato-Oncology Group, Department of Gastroenterology and Surgery, IRCCS National Cancer Institute, Milan, Italy
*Corresponding Author: Alessio Aghemo, Angela Maria e Antonio Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Via F. Sforza 35, 20122, Milan, Italy. Tel: +39-0255035432, Fax: +39-0250320410, E-mail: Email: [email protected]
Published online:Jun 30, 2012
Article type:Case Report
Received:May 07, 2012
Accepted:May 31, 2012
How to Cite:Aghemo A, Bhoori S, De Nicola S, Mazzaferro V, Colombo M. Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection. Hepat Mon. 2012;12(6):. doi: https://doi.org/10.5812/hepatmon.6135
Abstract
Background: Hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT) remains a serious problem in the clinical management of post-OLT patients. Recently, two case reports have described successful prevention of HCV liver graft reinfection with intravenous silibinin (SIL) monotherapy in two carriers of genotype 3a and 1a/4 HCV. Based on these findings, we decided to offer such a therapy to a 65 year old woman on the OLT list.
Case Presentation: A 65 year old patient with HCV 2a cirrhosis, a previous relapse to PegIFN and Rbv therapy, was listed for OLT due to hepatocellular carcinoma. She started SIL monotherapy 24 hours before OLT. After an initial HCV-RNA decline following surgery, a progressive HCV RNA increase was observed. For this reason, SIL was stopped after 15 days of monotherapy.
Conclusions: SIL has multiple anti-HCV mechanisms of action, most of them have been characterized in vitro only. Our case report shows that the antiviral effect of SIL might be HCV genotype dependent, as recently suggested by a study, showing no effect of SIL on the HCV-2a subgenomic replicon model. Our case reinforces the need for controlled studies to assess the efficacy of silibinin therapy in HCV infected patients before it can be broadly used in all clinical settings.
Implication for health policy/practice/research/medical education:
Silibinin monotherapy is a promising therapeutic option for HCV patients. Our article demonstrates that Silibinin has no effect on genotype 2 HCV, reinforcing the need for controlled studies on this drug before it can be routinely used in clinical practice.
Please cite this paper as:
Aghemo A, Bhoori S, De Nicola S, Mazzaferro V, Colombo M. Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection. Hepat Mon. 2012;12(6): 411-4. DOI: 10.5812/hepatmon.6135
Copyright © 2012 Kowsar Corp. All rights reserved.
Copyright
© 2012, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
12
Nov
2016
Successful Treatment of Acute Hepatitis C Virus (HCV) Infection with Interferon-Free Regimen in a Renal Transplant Patient: The First Case Report
Nawfal R Hussein,
Zana Sidiq Mohammed Saleem
Hussein NR, Saleem ZSM. Successful Treatment of Acute Hepatitis C Virus (HCV) Infection with Interferon-Free Regimen in a Renal Transplant Patient: The First Case Report. Int J Infect. 2017;4(4):e43268. doi: https://doi.org/10.17795/iji-43268
31
May
2011
Rosuvastatin and chronic hepatitis C
Eric M. Yoshida
Yoshida E. Rosuvastatin and chronic hepatitis C. Hepat Mon. 2011;11(5):. doi:
30
Apr
2016
Safety, Efficacy, and Tolerability of Sofosbuvir and Ribavirin in Management of Recurrent Hepatitis C Virus Genotype 4 After Living Donor Liver Transplant in Egypt: What Have We Learned so far?
Hany M. Dabbous,
Iman F. Montasser,
Mohamed A. Sakr,
Rasha Refai,
Moataz Sayam,
Ahmed Abdelmonem
,et al.Dabbous HM, Montasser IF, Sakr MA, Refai R, Sayam M, et al. Safety, Efficacy, and Tolerability of Sofosbuvir and Ribavirin in Management of Recurrent Hepatitis C Virus Genotype 4 After Living Donor Liver Transplant in Egypt: What Have We Learned so far?. Hepat Mon. 2016;16(5):e35339. doi: https://doi.org/10.5812/hepatmon.35339
28
Aug
2016
Sustained Virological Response After Six Weeks Treatment with a Sofosbuvir-Containing Regimen in a Patient Infected with Hepatitis C Virus Genotype 4: A Case Report
Nawfal R Hussein
Hussein NR. Sustained Virological Response After Six Weeks Treatment with a Sofosbuvir-Containing Regimen in a Patient Infected with Hepatitis C Virus Genotype 4: A Case Report. Int J Infect. 2017;4(3):e41216. doi: https://doi.org/10.5812/iji.41216
30
Jun
2011
Role of living donor liver transplantation in the treatment of hepatitis C virus infection
Georgios Tsoulfas,
Polyxeni Agorastou
Tsoulfas G, Agorastou P. Role of living donor liver transplantation in the treatment of hepatitis C virus infection. Hepat Mon. 2011;11(6):. doi:
Cited by
- Scopus by DOI: 5
Last Update: 3 weeks ago
- Scopus by Title: 5
Last Update: 3 weeks ago
- Scopus by Title (Ref): 14
Last Update: 3 weeks ago
- CrossRef: 14
Last Update: 1 day ago
Comments
Number of Comments:0